Ro 20-1724

Ro 20-1724 is a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase type 4 (PDE4), with an IC50 of approximately 2 μM. It acts by inhibiting the breakdown of cAMP, thereby increasing intracellular cAMP levels. Ro 20-1724 was originally developed by Roche and has been widely used in research to study the role of PDE4 in various physiological and pathological processes, including neuroprotection, learning and memory enhancement, anti-inflammatory effects, and modulation of immune responses. Although it showed some promise as a potential treatment for psoriasis, asthma, and septic shock in preclinical studies or early development stages, it was discontinued due to insufficient efficacy compared to existing therapies[1][3][4][5]. Ro 20-1724 is not approved for clinical use but remains a valuable tool compound in pharmacological research.

Other names

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone